Similar ex vivo data showed that peripheral blood mononuclear cells (PBMCs) derived from MS patients taken within 2 years of diagnosis produced higher levels of IL-17 in vitro compared with those taken from patients with long-standing disease[32]. Here, IL17A is linked to myeloid sarcoma.